According to Data Bridge Market Research new Market report, global hepatitis test solution/diagnosis market accounted to USD 2.61 billion in 2018 growing at a CAGR of 4.6% during the forecast period of 2019 to 2026.
Hepatitis is known as the inflammation of liver, which is of different types. It is also distinguished on the different types of viruses, Hepatitis A, B and C. Diagnosis of this disease is done through blood testing for each individual virus, also there is a method of testing for antibodies related to the virus. Also, there is a method of diagnosing the type of hepatitis by testing the genetic material or proteins in the body that are parts of the virus.
Global Hepatitis Test Solution/Diagnosis market is segmented on the basis of disease type, tests, technology, end-users and geography.
By Disease Type (Hepatitis B, Hepatitis C, Other), By Tests (Blood Tests, Imaging Tests, Liver Biopsy), By Technology (ELISA, Rapid Diagnostics Test, PCR, INAAT, Others), By End-User (Hospitals, Diagnostic Labs, Blood Banks, Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)
FACTORS DRIVING GROWTH IN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET
Increase of incidences of hepatitis disease worldwide
According to World Health Organization, Viral hepatitis B and C affects 325 million people worldwide. Hepatitis is the causes of liver cancer, which leads to 1.34 million deaths per year. According European Centre for Disease Prevention and Control (ECDC) the incidence rate of hepatitis B is 1.49 per 100 000 and hepatitis C is 8.7 per 100 000 in the WHO European Member States.
In November 2017, new data was presented at the World Hepatitis Summit held in Sao Paulo, Brazil from 1-4 November, 2017 that estimated around 52 million children living with viral hepatitis. This burden on children could be lessened with testing of the virus which is expected to increase the need for virus testing.
Few of the major competitors currently working in the hepatitis test solution/diagnosis market are F. Hoffmann-La Roche Ltd, Abbott, Bio-Rad Laboratories Inc., Siemens AG, DiaSorin, QIAGEN, Danaher, bioMérieux SA, Grifols S.A., Ortho Clinical Diagnostics, FUJIREBIO Inc., Avantor Inc., Quest Diagnostics Incorporated, MedMira Inc., Laboratory Corporation of America Holdings, Cigna, and OraSure Technologies Inc.
Browse Related Reports:
Global Injectable Drug Delivery Market, Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Application (Hormonal Disorders, orphan disease, other applications), Usage Pattern, Mode Of Administration, End User (Hospitals And Clinics, Home Healthcare Settings, Research Laboratories, Pharmaceutical And Biotechnological Companies, Other End Users), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tender, Online Pharmacy),Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2025
Global Leukemia Therapeutics Market, By Disease Type (Chronic Lymphatic Leukemia, Acute Lymphatic Leukemia), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Surgery), By Stages (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East & Africa)– Industry Trends and Forecast to 2025
Global Hepatitis Test Solution/Diagnosis Market – Industry Trends and Forecast to 2028